YUYU PHARMA, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,635 KRW | -1.28% |
|
+0.98% | -12.22% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 61,527 | 66,725 | 108,199 | 130,082 | 102,750 | 85,445 |
| Enterprise Value (EV) 1 | 61,225 | 66,821 | 107,646 | 118,985 | 111,249 | 92,497 |
| P/E ratio | 18.7 x | 15.1 x | 90.7 x | -49.7 x | -16.4 x | -11.9 x |
| Yield | 1.9% | 1.85% | 1.44% | 1.34% | 1.69% | - |
| Capitalization / Revenue | 0.74 x | 0.73 x | 1.1 x | 1.12 x | 0.74 x | 0.62 x |
| EV / Revenue | 0.74 x | 0.74 x | 1.1 x | 1.03 x | 0.8 x | 0.67 x |
| EV / EBITDA | 8.21 x | 5.97 x | 10.6 x | 20.9 x | 25.1 x | 19 x |
| EV / FCF | -11.1 x | 13.7 x | -5.88 x | -88.1 x | -9.14 x | -12.3 x |
| FCF Yield | -8.99% | 7.3% | -17% | -1.14% | -10.9% | -8.14% |
| Price to Book | 0.73 x | 0.76 x | 0.96 x | 1.07 x | 0.89 x | 0.78 x |
| Nbr of stocks (in thousands) | 11,719 | 11,758 | 14,822 | 16,656 | 16,519 | 16,183 |
| Reference price 2 | 5,250 | 5,675 | 7,300 | 7,810 | 6,220 | 5,280 |
| Announcement Date | 3/20/19 | 3/18/20 | 3/17/21 | 3/23/22 | 3/22/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 83,096 | 90,878 | 98,120 | 115,655 | 138,881 | 137,210 |
| EBITDA 1 | 7,455 | 11,195 | 10,170 | 5,703 | 4,435 | 4,858 |
| EBIT 1 | 5,328 | 8,075 | 6,271 | 1,200 | -592.1 | -748.9 |
| Operating Margin | 6.41% | 8.89% | 6.39% | 1.04% | -0.43% | -0.55% |
| Earnings before Tax (EBT) 1 | 4,648 | 6,600 | 3,711 | -383.2 | -3,810 | -5,442 |
| Net income 1 | 4,020 | 4,722 | 1,284 | -2,214 | -5,988 | -7,181 |
| Net margin | 4.84% | 5.2% | 1.31% | -1.91% | -4.31% | -5.23% |
| EPS 2 | 281.5 | 376.3 | 80.44 | -157.0 | -378.3 | -443.0 |
| Free Cash Flow 1 | -5,505 | 4,880 | -18,305 | -1,351 | -12,176 | -7,527 |
| FCF margin | -6.63% | 5.37% | -18.66% | -1.17% | -8.77% | -5.49% |
| FCF Conversion (EBITDA) | - | 43.59% | - | - | - | - |
| FCF Conversion (Net income) | - | 103.34% | - | - | - | - |
| Dividend per Share 2 | 100.0 | 105.0 | 105.0 | 105.0 | 105.0 | - |
| Announcement Date | 3/20/19 | 3/18/20 | 3/17/21 | 3/23/22 | 3/22/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 96.3 | - | - | 8,499 | 7,053 |
| Net Cash position 1 | 302 | - | 553 | 11,097 | - | - |
| Leverage (Debt/EBITDA) | - | 0.008604 x | - | - | 1.916 x | 1.452 x |
| Free Cash Flow 1 | -5,505 | 4,880 | -18,305 | -1,351 | -12,176 | -7,527 |
| ROE (net income / shareholders' equity) | 5.08% | 6.27% | 2.32% | -0.75% | -3.51% | -4.55% |
| ROA (Net income/ Total Assets) | 2.59% | 3.7% | 2.68% | 0.43% | -0.19% | -0.24% |
| Assets 1 | 154,978 | 127,702 | 47,916 | -513,404 | 3,141,489 | 3,018,454 |
| Book Value Per Share 2 | 7,210 | 7,433 | 7,579 | 7,306 | 6,986 | 6,773 |
| Cash Flow per Share 2 | 2,301 | 2,283 | 1,362 | 3,018 | 1,580 | 1,892 |
| Capex 1 | 9,763 | 8,056 | 12,047 | 6,073 | 5,283 | 4,514 |
| Capex / Sales | 11.75% | 8.87% | 12.28% | 5.25% | 3.8% | 3.29% |
| Announcement Date | 3/20/19 | 3/18/20 | 3/17/21 | 3/23/22 | 3/22/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.22% | 54.48M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B | |
| +3.90% | 1.65B |
- Stock Market
- Equities
- A000220 Stock
- Financials Yuyu Pharma, Inc.
